Taxane‑induced polyneuropathy – current possibilities of prediction and management

Česká verzia

Authors: Magdaléna Jablonická ¹; Lucia Žideková ²; Beata Mladosievičová ³
Authors place of work: Onkologická klinika SZU, FNsP F. D. Roosevelta, Banská Bystrica ¹; Oddelenie genetiky, Medirex, a. s., Bratislava ²; Oddelenie klinickej patofyziológie, Lekárska fakulta UK, Bratislava ³
Published in the journal: Vnitř Lék 2021; 67(1): 26-31
Category:

Summary

Peripheral neurotoxicity is the most typical non-haematological adverse effect of taxanes. Symptoms are dominated by sensory peripheral neuropathy, the incidence and degree of which depend on the cumulative dose level. The impact of neurotoxicity on the patient´s quality of life is significant, therefore it is necessary to consider the selection of therapy and the patient´s pre-existing risk factors for developing neuropathy and to get acquainted with current management options, including genetic prediction of polyneuropathy. This review article reports on a very common complication of cancer therapy that can be encountered at each internist´s outpatient dispensary.

Keywords:

paclitaxel – polyneuropathy – paresthesia – risk factors – duloxetine

Zdroje

1. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997; 48: 353–374. Dostupné z DOI: .

2. Gelderblom H, Verveij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001; 37: 1590–1598. Dostupné z DOI: .

3. Barilla R, Šálek T. Nanopartikulové technológie, nab-paklitaxel a nové možnosti v liečbe vybraných nádorových chorôb. Onkológia (Bratisl.), 2014; 9(4): 253–256.

4. Adam Z, Vorlíček J, Sedláčková Š. Přehled protinádorové farmakologické léčby. Praktické Lékárenství 2005; 2: 76–80

5. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother. Pharmacol. 2015; 75: 659–670. Dostupné z DOI: .

6. Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta -analysis. Cancer Treat Rev. 2012; 38 (6): 613– 617. Dostupné z DOI: .

7. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008; 112: 1455–1461.Dostupné z DOI: .

8. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23: 5542–5551. Dostupné z DOI: .

9. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004; 11(1): 82–85. Dostupné z DOI: .

10. Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, de Negri O, Tredici G. Effect on the peripheral nervous system of the short -term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18: 137–145.

11. Addington J, Freimer M. Chemotherapy -induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016; 5. pii: F1000 Faculty Rev-1466. Dostupné z DOI: .

12. Loprinzi, CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le -Lindqwister NA, Soori GS, Jaslowski AJ et al. Natural history of paclitaxel -associated acute pain syndrome: Prospective cohort study NCCTG N08C1. J. Clin. Oncol. 2011; 29: 1472–1478. Dostupné z DOI: .

13. Tofthagen C, McAllister RD, Visovsky C. Peripheral neuropathy caused by paclitaxel and docetaxel: An evaluation and comparison of symptoms. J. Adv. Pract. Oncol. 2013; 4: 204–215.

14. Jerian SM, Sarosy GA, Link CJ, Fingert HJ, Reed E, Kohn EC. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol. Oncol. 1993; 51: 277–280. Dostupné z DOI: .

15. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD. Association between patient reported outcomes and quantitative sensory tests for measuring long -term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res. Treat. 2011; 125: 767–774. Dostupné z DOI: .

16. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, et al. NCCN task force report: Management of neuropathy in cancer. J. Natl. Compr. Cancer Netw. 2009; 7 (suppl. 5), S1–S26. Dostupné z DOI: .

17. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram, S, Urba WJ, Pritchard KI, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 2005; 23: 5542–5551. Dostupné z DOI: .

18. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy -Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016; 34(25): 3014–3022. Dostupné z DOI: .

19. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 1997; 8: 187– 190. Dostupné z DOI: .

20. Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, Chung MW, Han SY, Shin HD: Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. 17(6): 479–484, 2013. Dostupné z DOI: .

21. Kus T, Aktasi G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul A, Camci C: Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. 9: 5073–5080, 2016. Dostupné z DOI: .

22. Lam SW, Frederiks CN, Straaten T, Honkoop AH, Guchelaar HJ, Boven E: Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel -treated breast cancer patients. British Journal of Cancer. 115: 1335–1342, 2016. Dostupné z DOI: .

23. Baldwin RM, Owzar K, Zembztsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgensen EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL: A Genome -Wide Association Study Identifies Novel Loci for Paclitaxel -Induced Sensory Peripheral Neuropathy in CALGB 40101. 18(18): 5099– 5109, 2012. Dostupné z DOI: .

24. Schloss JM, Colosimo M, Airey C, Masci PP, Linnane A.W., Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr. 2013; 32(6): 888–893. doi: 10.1016/j.clnu.2013. 04. 007. Epub 2013 Apr 13. Dostupné z DOI: .

25. Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized Double -Blind Placebo -Controlled Trial of Acetyl -L-Carnitine for the Prevention of Taxane -Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. J Clin Oncol. 2013; 31(20): 2627–2633. Dostupné z DOI: .

26. Sato J, Mori M, Nihei S, et al. The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. J Pharm Health Care Sci. 2016; 2: 33. DOI: .

27. Bednařík J, Ambler Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený M. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93–101.

28. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh DA, Wong GY. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double -blind, placebo -controlled, crossover trial (N00C3). Cancer. 2007 Nov 1; 110(9): 2110–2118. Dostupné z DOI: .

29. Smith EM, Pang H, Cirrincione C, Fleishman C, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le -Lindqwister N, Gilman PB, Shapiro CL. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy -induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13): 1359–1367. Dostupné z DOI: .

30. Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008; 35(1): 31–39. Epub 2007 Nov 5. Dostupné z DOI: .

31. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double -blind, placebo -controlled trial, N01C3. Cancer 112(12): 2802–2808. Dostupné z DOI: .

32. Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment -related neuropathic pain: proof of concept study with menthol–a TRPM8 agonist. Support Care Cancer. 2015; 23: 2769– 2777. Dostupné z DOI: .

33. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL. A double -blind, placebo-controlled trial of a topical treatment for chemotherapy -induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011; 19(6): 833–841. Dostupné z DOI: .

34. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le -Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy -induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13): 1359–1367. Dostupné z DOI: .

35. Su Y, Huang J, Wang S, Unger JM, Arias -Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J, Yuan Z. The Effects of Ganglioside -Monosialic Acid in Taxane -Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 2020; 112(1): 55–62. Dostupné z DOI: .

36. White CM, Pritchard J, Turner -Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev 2004; (4): CD003904. Dostupné z DOI: .

37. Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, Schepansky A, Capstick V, Courneya KS. Physical activity in ovarian cancer survivors : associations with fatigue, sleep, and psychosocial functioning. Dostupné z DOI: .

38. Lopez D, Eng C, Overman MJ, Liu W, Cohen L, Ramirez DL, Beinhorn CM, Sumler PA, Chen M, Bruera E, Prinsloo S, Li Y. A pilot study of oncology massage to treat chemotherapy- -induced peripheral neuropathy (CIPN). Journal of Clinical Oncology 37,no. 15_suppl. Dostupné z DOI: .

39. Loprinzi C: Novel therapeutics for chemotherapy -induced neuropathy. 2019 MASCC/ ISOO International Symposium on Supportive Care in Cancer. Abstract eP720. Presented June 21, 2019. 40. https://clinicaltrials.gov/ct2/show/NCT04205903